RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF
Radiopharm Theranostics Ltd
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Sep 30, 2026
$0.96−0.07 (-6.50%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Radiopharm Theranostics statistics
Financials through Jun 30, 2025, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Market Cap | $3.41B | $197.05M |
| Enterprise Value | $3.38B | $106.56M |
| PS Ratio | 939.36 | 3.93 |
Enterprise value
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| EV / Sales | 930.82 | 2.69 |
Income (trailing twelve months)
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Revenue | $3.63M | $57.94M |
| Gross Profit | $39.28K | $90.47M |
| Operating Income | -$38.17M | -$21.44M |
| Pretax Income | -$38.24M | -$14.45M |
| EBITDA | -$35.58M | -$16.91M |
| EPS (Diluted) | -$1.76 | -$0.83 |
Margins
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Gross Margin | 1.08% | 52.3% |
| Operating Margin | -1050.6% | -44.5% |
| Pretax Margin | -1052.4% | -13.0% |
| EBITDA Margin | -979.2% | -31.3% |
Returns
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Return on Capital Employed (ROCE) | -53.4% | -37.8% |
Growth
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 1114.3% | 6.01% |
Balance sheet
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $29.12M | $62.42M |
| Net Cash (Debt) | $29.12M | $15.68M |
| Net Cash Per Share | $0.01 | $0.65 |
| Working Capital | $24.92M | $75.77M |
Financial position
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Current Ratio | 2.67 | 3.30 |
| Quick Ratio | 2.65 | 2.39 |
| Interest Coverage | -584.59 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Operating Cash Flow | -$36.65M | -$12.35M |
Efficiency
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Asset Turnover | 0.04 | 0.38 |
| Revenue Per Employee | $1.82M | $398.96K |
| Employee Count | 2 | 73 |
Dividends and yields
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Buyback Yield | -1.58% | -0.58% |
| Shareholder Yield | -1.58% | 0.00% |
Shares
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Shares Outstanding | 3,544,220,000 | 59,128,900 |
| Shares Change (YoY) | 438.5% | 11.1% |
| Float | 2,570,200,000 | 48,744,500 |
| Shares Held by Insiders | 27.5% | 11.8% |
| Shares Held by Institutions | 1.44% | 59.4% |
Taxes
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Income Tax | $103.29K | $91.50K |
Scores
| Measure | Radiopharm Theranostics | Industry median |
|---|---|---|
| Altman Z-Score | 45.89 | 0.10 |
Calculated by StockData from Radiopharm Theranostics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.